LENZ Selling General Administrative vs Cost Of Revenue Analysis

LENZ Stock

37.30 1.05 2.90%

LENZ Therapeutics financial indicator trend analysis is infinitely more than just investigating LENZ Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether LENZ Therapeutics is a good investment. Please check the relationship between LENZ Therapeutics Selling General Administrative and its Cost Of Revenue accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LENZ Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.

Selling General Administrative vs Cost Of Revenue

Selling General Administrative vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of LENZ Therapeutics Selling General Administrative account and Cost Of Revenue. At this time, the significance of the direction appears to have strong relationship.

The correlation between LENZ Therapeutics' Selling General Administrative and Cost Of Revenue is 0.77. Overlapping area represents the amount of variation of Selling General Administrative that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of LENZ Therapeutics, assuming nothing else is changed. The correlation between historical values of LENZ Therapeutics' Selling General Administrative and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling General Administrative of LENZ Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Selling General Administrative i.e., LENZ Therapeutics' Selling General Administrative and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Selling General Administrative

Cost Of Revenue

Cost of Revenue is found on LENZ Therapeutics income statement and represents the costs associated with goods and services LENZ Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from LENZ Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into LENZ Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in LENZ Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy LENZ Stock please use our How to Invest in LENZ Therapeutics guide.At this time, LENZ Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.73 in 2024, whereas Selling General Administrative is likely to drop slightly above 3.8 M in 2024.

	2023	2024 (projected)
Interest Expense	36K	48K
Depreciation And Amortization	2.4M	2.6M

Interest Expense Depreciation And Amortization

LENZ Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Short Term Debt	Property Plant And Equipment Net	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Net Invested Capital	Property Plant And Equipment Gross	Capital Stock	Net Working Capital	Common Stock
Total Assets		0.43	0.35	0.32	1.0	-0.85	-0.74	0.85	1.0	-0.41	0.44	1.0	-0.83	0.78	0.29	0.72	0.97	-0.35	0.84	0.91	0.35	-0.64	0.6	0.35	0.59	-0.35
Short Long Term Debt Total	0.43		0.71	0.75	0.4	-0.18	0.08	0.24	0.4	0.27	0.81	0.41	-0.44	0.73	0.57	0.68	0.25	0.51	0.69	0.34	-0.55	0.09	-0.09	-0.53	-0.13	0.51
Other Current Liab	0.35	0.71		1.0	0.3	-0.28	-0.28	0.29	0.35	-0.05	0.93	0.35	-0.73	0.31	0.16	0.29	0.28	0.0	0.32	0.28	0.0	-0.14	0.14	0.0	0.13	0.0
Total Current Liabilities	0.32	0.75	1.0		0.26	-0.22	-0.23	0.23	0.31	-0.01	0.94	0.31	-0.7	0.33	0.22	0.32	0.23	0.06	0.31	0.23	-0.07	-0.12	0.11	-0.06	0.1	0.06
Total Stockholder Equity	1.0	0.4	0.3	0.26		-0.86	-0.73	0.86	1.0	-0.4	0.39	1.0	-0.8	0.77	0.27	0.71	0.97	-0.35	0.84	0.92	0.35	-0.62	0.6	0.36	0.59	-0.35
Net Debt	-0.85	-0.18	-0.28	-0.22	-0.86		0.66	-0.99	-0.88	0.37	-0.18	-0.88	0.72	-0.38	0.25	-0.27	-0.92	0.47	-0.72	-0.96	-0.49	0.38	-0.36	-0.48	-0.38	0.47
Retained Earnings	-0.74	0.08	-0.28	-0.23	-0.73	0.66		-0.62	-0.75	0.7	-0.32	-0.75	0.83	-0.32	-0.05	-0.35	-0.81	0.8	-0.26	-0.58	-0.85	0.92	-0.89	-0.84	-0.9	0.8
Cash	0.85	0.24	0.29	0.23	0.86	-0.99	-0.62		0.88	-0.26	0.2	0.88	-0.7	0.43	-0.21	0.31	0.92	-0.37	0.77	0.96	0.41	-0.33	0.34	0.43	0.36	-0.37
Cash And Short Term Investments	1.0	0.4	0.35	0.31	1.0	-0.88	-0.75	0.88		-0.4	0.42	1.0	-0.83	0.74	0.23	0.68	0.98	-0.36	0.84	0.93	0.37	-0.62	0.59	0.38	0.58	-0.36
Common Stock Shares Outstanding	-0.41	0.27	-0.05	-0.01	-0.4	0.37	0.7	-0.26	-0.4		-0.08	-0.41	0.48	-0.07	0.04	-0.11	-0.44	0.89	0.01	-0.37	-0.72	0.72	-0.47	-0.55	-0.48	0.89
Total Liab	0.44	0.81	0.93	0.94	0.39	-0.18	-0.32	0.2	0.42	-0.08		0.42	-0.74	0.57	0.52	0.58	0.31	0.08	0.39	0.24	-0.09	-0.31	0.3	-0.08	0.27	0.08
Total Current Assets	1.0	0.41	0.35	0.31	1.0	-0.88	-0.75	0.88	1.0	-0.41	0.42		-0.83	0.75	0.24	0.69	0.98	-0.36	0.84	0.92	0.37	-0.62	0.59	0.38	0.59	-0.36
Short Term Debt	-0.83	-0.44	-0.73	-0.7	-0.8	0.72	0.83	-0.7	-0.83	0.48	-0.74	-0.83		-0.53	-0.17	-0.52	-0.82	0.48	-0.54	-0.69	-0.5	0.68	-0.65	-0.5	-0.65	0.48
Property Plant And Equipment Net	0.78	0.73	0.31	0.33	0.77	-0.38	-0.32	0.43	0.74	-0.07	0.57	0.75	-0.53		0.78	0.99	0.62	0.19	0.83	0.57	-0.21	-0.41	0.4	-0.19	0.36	0.19
Accounts Payable	0.29	0.57	0.16	0.22	0.27	0.25	-0.05	-0.21	0.23	0.04	0.52	0.24	-0.17	0.78		0.86	0.08	0.36	0.32	-0.06	-0.38	-0.35	0.34	-0.36	0.28	0.36
Non Current Assets Total	0.72	0.68	0.29	0.32	0.71	-0.27	-0.35	0.31	0.68	-0.11	0.58	0.69	-0.52	0.99	0.86		0.55	0.16	0.72	0.45	-0.18	-0.49	0.47	-0.16	0.43	0.16
Non Currrent Assets Other	0.97	0.25	0.28	0.23	0.97	-0.92	-0.81	0.92	0.98	-0.44	0.31	0.98	-0.82	0.62	0.08	0.55		-0.48	0.75	0.92	0.52	-0.65	0.64	0.53	0.64	-0.48
Other Assets	-0.35	0.51	0.0	0.06	-0.35	0.47	0.8	-0.37	-0.36	0.89	0.08	-0.36	0.48	0.19	0.36	0.16	-0.48		0.15	-0.35	-0.95	0.7	-0.56	-0.85	-0.6	1.0
Non Current Liabilities Total	0.84	0.69	0.32	0.31	0.84	-0.72	-0.26	0.77	0.84	0.01	0.39	0.84	-0.54	0.83	0.32	0.72	0.75	0.15		0.85	-0.17	-0.14	0.13	-0.15	0.11	0.15
Other Current Assets	0.91	0.34	0.28	0.23	0.92	-0.96	-0.58	0.96	0.93	-0.37	0.24	0.92	-0.69	0.57	-0.06	0.45	0.92	-0.35	0.85		0.31	-0.36	0.29	0.29	0.3	-0.35
Other Stockholder Equity	0.35	-0.55	0.0	-0.07	0.35	-0.49	-0.85	0.41	0.37	-0.72	-0.09	0.37	-0.5	-0.21	-0.38	-0.18	0.52	-0.95	-0.17	0.31		-0.73	0.69	0.97	0.73	-0.95
Net Invested Capital	-0.64	0.09	-0.14	-0.12	-0.62	0.38	0.92	-0.33	-0.62	0.72	-0.31	-0.62	0.68	-0.41	-0.35	-0.49	-0.65	0.7	-0.14	-0.36	-0.73		-0.94	-0.71	-0.94	0.7
Property Plant And Equipment Gross	0.6	-0.09	0.14	0.11	0.6	-0.36	-0.89	0.34	0.59	-0.47	0.3	0.59	-0.65	0.4	0.34	0.47	0.64	-0.56	0.13	0.29	0.69	-0.94		0.75	1.0	-0.56
Capital Stock	0.35	-0.53	0.0	-0.06	0.36	-0.48	-0.84	0.43	0.38	-0.55	-0.08	0.38	-0.5	-0.19	-0.36	-0.16	0.53	-0.85	-0.15	0.29	0.97	-0.71	0.75		0.79	-0.85
Net Working Capital	0.59	-0.13	0.13	0.1	0.59	-0.38	-0.9	0.36	0.58	-0.48	0.27	0.59	-0.65	0.36	0.28	0.43	0.64	-0.6	0.11	0.3	0.73	-0.94	1.0	0.79		-0.6
Common Stock	-0.35	0.51	0.0	0.06	-0.35	0.47	0.8	-0.37	-0.36	0.89	0.08	-0.36	0.48	0.19	0.36	0.16	-0.48	1.0	0.15	-0.35	-0.95	0.7	-0.56	-0.85	-0.6

Click cells to compare fundamentals

LENZ Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for LENZ Stock Analysis

When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

LENZ Selling General Administrative vs Cost Of Revenue Analysis

Selling General Administrative vs Cost Of Revenue

Selling General Administrative vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Selling General Administrative

Cost Of Revenue

LENZ Therapeutics fundamental ratios Correlations

LENZ Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for LENZ Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Cash	- 0.99	Net Debt
Other Current Assets	- 0.96	Net Debt
Common Stock	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.95	Other Assets
Net Working Capital	- 0.94	Net Invested Capital
Property Plant And Equipment Gross	- 0.94	Net Invested Capital